Published in Cancer Weekly, October 20th, 1997
Initial findings from a Phase III clinical study for the treatment of psoriasis and a Phase III trial to treat cutaneous T-cell lymphoma (CTCL) demonstrated no statistical differences in the achievement of study endpoints between BCX-34-treated and placebo groups.
The primary endpoint for the Company's Phase III CTCL trial was a 50 percent or greater decrease in body surface area covered with patch and plaque cancerous lesions during the six-month course of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.